# [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

> **NCT02608216** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 20 (estimated)

## Conditions studied

- Breast Neoplasm
- Metastatic Breast Cancer
- Rb+ Breast Cancer

## Interventions

- **DRUG:** [18F]FLT
- **DEVICE:** PET/CT
- **DRUG:** ribociclib
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT02608216
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-11
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02608216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02608216, "[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02608216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*